Login to Your Account



Takeda's Entyvio gets FDA nod in ulcerative colitis, Crohn's disease

By Jennifer Boggs
Managing Editor

Wednesday, May 28, 2014

Coming as little surprise after an FDA advisory panel backed Entyvio (vedolizumab) for treatment of severe ulcerative colitis and moderate to severe Crohn's disease, Takeda Pharmaceutical Co. Ltd.'s drug gained approval on its May 20 PDUFA date, becoming the first integrin inhibitor to hit the market since Biogen Idec Inc.'s Tysabri (natalizumab).

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription